MedTrace Logo

CLinical Utility of the omnigrAf® biomarkeR Panel In The Care of kidneY Transplant Recipients

NCT05482100 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2022-08-01

No results posted yet for this study

Summary

This is a prospective, multi-site, observational study with a matched control group. The primary objective is to evaluate change in renal function over time in recipients of kidney transplants who are undergoing OmniGrafTM monitoring in conjunction with patient medication-related burden monitoring.

Conditions

  • Kidney Transplant Rejection

Interventions

DIAGNOSTIC_TEST

Patients monitored with OmniGraf testing

This is an observational study there are no protocol mandated interventions. OmniGraf results will be utilized in conjunction with standard of care assessments to determine patient management.

Sponsors & Collaborators

  • Transplant Genomics, Inc.

    lead INDUSTRY

Principal Investigators

  • Patty West-Thielke, PharmD · Transplant Genomics

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2026-06-01
Completion
2026-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05482100 on ClinicalTrials.gov